Novel HER2 blockade treatments continue to show promise in thirdline setting for metastatic breast cancer

Novel HER2 blockade treatments continue to show promise in third-line setting for metastatic breast cancer

11:43 EDT 10 Jun 2019 | Pharmaceutical Technology

During this year’s American Society of Clinical Oncology (ASCO 2019) meeting in Chicago, two new third-line treatment options were discussed,...
Read More...

More From BioPortfolio on "Novel HER2 blockade treatments continue to show promise in third-line setting for metastatic breast cancer"